The stock of NanoString Technologies Inc (NASDAQ:NSTG) reached all time high today, Nov, 14 and still has $32.50 target or 44.00% above today’s $22.57 share price. This indicates more upside for the $474.69 million company. This technical setup was reported by Barchart.com. If the $32.50 PT is reached, the company will be worth $208.86M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 121,260 shares traded hands. NanoString Technologies Inc (NASDAQ:NSTG) has risen 46.90% since April 12, 2016 and is uptrending. It has outperformed by 41.91% the S&P500.
According to Zacks Investment Research, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 2.52 in Q2 2016. Its up 1.31, from 1.21 in 2016Q1. The ratio increased, as 9 funds sold all NanoString Technologies Inc shares owned while 12 reduced positions. 15 funds bought stakes while 38 increased positions. They now own 16.55 million shares or 3.90% more from 15.93 million shares in 2016Q1.
Amer Grp Inc accumulated 8,528 shares or 0% of the stock. Blackrock Fund Advisors owns 639,372 shares or 0% of their US portfolio. First Light Asset Management Ltd has 118,547 shares for 0.69% of their US portfolio. Rs Inv Management Llc owns 27,050 shares or 0% of their US portfolio. Ghost Tree Ltd Llc has invested 0.91% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG). Citigroup, a New York-based fund reported 3,856 shares. Morgan Stanley accumulated 0.01% or 1.55M shares. Nicholas Prns Ltd Partnership has invested 0.14% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG). Millennium Mngmt Ltd Liability accumulated 0.01% or 458,162 shares. Blackrock Institutional Tru Company Na last reported 0% of its portfolio in the stock. Prudential Inc holds 0% or 10,345 shares in its portfolio. State Street Corp reported 181,377 shares or 0% of all its holdings. Blackrock Inc accumulated 759 shares or 0% of the stock. Driehaus Capital Management Limited Liability Com accumulated 189,016 shares or 0.08% of the stock. Dsc Advisors Limited Partnership last reported 465,000 shares in the company.
Insider Transactions: Since August 12, 2016, the stock had 0 buys, and 7 selling transactions for $9.39 million net activity. WAITE CHARLES P JR had sold 111,060 shares worth $1.84 million on Friday, August 26. The insider BURNS WAYNE sold $65,357.
Another recent and important NanoString Technologies Inc (NASDAQ:NSTG) news was published by Quotes.Wsj.com which published an article titled: “News NanoString Technologies Inc.NSTG” on May 20, 2013.
NSTG Company Profile
NanoString Technologies, Inc., incorporated on June 20, 2003, develops, makes and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Firm operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Firm markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use. The Company’s molecular diagnostic product Prosigna Breast Cancer Assay, or Prosigna, provides an assessment of a patient’s risk of recurrence for breast cancer. The Firm has an installed base of over 350 systems, which its clients have used to publish more than 1,000 peer-reviewed papers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.